On September 6, 2022 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, reported that Mina Sooch, MBA, Founder and CEO will present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022 (Press release, Ocuphire Pharma, SEP 6, 2022, View Source [SID1234619082]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 24th Annual Global Investment Conference – September 12-14, 2022

If you are interested in arranging a 1×1 meeting request, please contact your bank/conference representative or [email protected]. For more details, please see the Investors and Events section of Ocuphire’s corporate website.